quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:03:00·253d
PRRelease
Alto Neuroscience Inc. logo
Cerevel Therapeutics Holdings Inc. logo
Rapport Therapeutics Inc. logo

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

ANRO· Alto Neuroscience Inc.CERE· Cerevel Therapeutics Holdings Inc.RAPP· Rapport Therapeutics Inc.
Health Care
Original source

Companies

  • ANRO
    Alto Neuroscience Inc.
    Health Care
  • CERE
    Cerevel Therapeutics Holdings Inc.
    Health Care
  • RAPP
    Rapport Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 10RAPPUpdateRaymond James$66.00
  • Feb 2RAPPUpdateWells Fargo$43.00
  • Jan 5ANROUpdateChardan Capital Markets$30.00
  • Nov 19RAPPUpdateBTIG Research$47.00
  • Nov 17ANROUpdateBTIG Research-
  • Sep 29ANROUpdateChardan Capital Markets$15.00

Related

  • SEC16h
    SEC Form DEFA14A filed by Rapport Therapeutics Inc.
  • SEC16h
    SEC Form DEF 14A filed by Rapport Therapeutics Inc.
  • INSIDER2d
    SEC Form 4 filed by Third Rock Ventures V, L.P.
  • INSIDER2d
    SEC Form 4 filed by Yeleswaram Krishnaswamy
  • SEC2d
    Rapport Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR2d
    Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
  • PR2d
    Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
  • SEC2d
    SEC Form EFFECT filed by Alto Neuroscience Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022